Description
Description
This page contains brief details about the drug temozolomide, it’s indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.
Date of Approval
Temozolomide is an anti-neoplastic drug that belongs to the alkylating agent-triazine group. It was approved by the FDA on August 11, 1999, for treating certain brain cancers.
Mechanism of Action of Temozolomide
Temozolomide belongs to alkylating agents. It works by stopping cancer cells from dividing and resulting in cell death. Temozolomide is not directly active, but it is quickly converted into an active metabolite that breaks the DNA strands, causing cell death.
Uses of Temozolomide
Temozolomide is an alkylating drug used to treat adults with newly diagnosed glioblastoma multiforme (one of the fast-growing cancers that occur in the brain and spinal cord). It is given along with radiotherapy and then as maintenance treatment. It is also indicated to treat refractory anaplastic astrocytoma who have experienced disease progression on a drug therapy containing nitrosourea and procarbazine hydrochloride.
Temozolomide Dosage available
Temozolomide is a prescription drug available as an oral capsule and powder for injection. The drug will be prescribed by the healthcare professional. Your physician will determine the medicine’s dose, dosage form, and frequency.
Generally, for treating Refractory Anaplastic astrocytoma of the brain initially, 150mg/m² as a capsule or injection is given once every day for five days followed by a 23-day break before repeating the next dosage cycle. Then during the maintenance phase dose may be increased or maintained at 200 mg/m² orally or intravenously once every day for five days, followed by a 28-day cycle if the absolute neutrophil count is more than >1500 mm³ and platelets are more than >100,000 mm³. For treating glioblastoma Multiforme initially temozolomide 75 mg/m² orally or intravenously is given once every day for 42 days along with the radiotherapy.
